AbbVie (ABBV) Cash from Operations (QoQ) (2012 - 2026)
AbbVie (ABBV) Cash from Operations (QoQ) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.62% |
| Dec 31, 2025 | -25.71% |
| Sep 30, 2025 | 36.31% |
| Jun 30, 2025 | 215.17% |
| Mar 31, 2025 | -76.80% |
| Dec 31, 2024 | 29.39% |
| Sep 30, 2024 | 139.85% |
| Jun 30, 2024 | -43.79% |
| Mar 31, 2024 | -15.00% |
| Dec 31, 2023 | -37.25% |
| Sep 30, 2023 | 19.86% |
| Jun 30, 2023 | 50.70% |
| Mar 31, 2023 | -43.55% |
| Dec 31, 2022 | -2.29% |
| Sep 30, 2022 | 51.89% |
| Jun 30, 2022 | 1.98% |
| Mar 31, 2022 | -3.29% |
| Dec 31, 2021 | -36.04% |
| Sep 30, 2021 | 62.27% |
| Jun 30, 2021 | 0.27% |